Study authors from the University of Washington, Seattle, and Veterans Affairs Puget Sound Healthcare System in Seattle sought to investigate whether HCV eradication with DAAs could lower the risk of liver cancer in patients.

Data from a retrospective cohort study presented at The Liver Meeting® 2016 has shown that hepatitis C virus (HCV)-infected patients with advanced chronic kidney disease (CKD) "remains a challenging population to treat," with <10% receiving treatment in the early direct-acting antivirals (DAA) era.

Ledipasvir/Sofosbuvir with or without ribavirin is associated with comparable sustained virologic response (SVR) rates for African American patients and non-African Americans who have HIV/HCV co-infection, but cirrhosis was associated with significantly poorer rates.

Patients with HCV GT1 with decompensated cirrhosis treated in the real world with ledipasvir/sofosbuvir plus ribavirin achieved high cure rates and comparable MELD improvement to patients in clinical trials.

The prevalence of chronic liver diseases has more than doubled in the past 30 years among adolescents and young adults in the United States to about 25%, according to research presented at The Liver Meeting® 2016.